Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Optim Oncology, Urology Centers of Oklahoma join U.S. Oncology Network

Monday, August 4, 2014 01:59 PM

Optim Oncology and Urology Centers of Oklahoma, divisions of Oklahoma Multispecialty Group, have joined U.S. Oncology Network, a network of integrated, community-based, physician-owned oncology practices dedicated to advancing high-quality, evidence-based cancer care.

More... »

WIRB Copernicus Group

Molecular Profiles, Xenogesis partner

Monday, August 4, 2014 01:57 PM

Molecular Profiles, a contract development and manufacturing organization (CDMO) subsidiary of Columbia Laboratories, and CRO XenoGesis are collaborating to support pharmaceutical and biotech drug developers during the preclinical and formulation development stage. Molecular Profiles' pharmaceutical development services will be supported by XenoGesis' experience in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound's bioavailability.  

More... »


The Pulse on Global Trials

Monday, August 4, 2014 07:00 AM

As innovations in global healthcare continue to be explored, there is a heightened urgency among industry professionals to understand the rules of clinical trial recruitment, how they vary by region and what they mean for using digital channels such as online advertising, search engine marketing and social media to engage prospective participants.

More... »

The CenterWatch Monthly, August 2014

Friday, August 1, 2014 01:46 PM

Reality of costs and impact rain on Sunshine Act

More... »

MGC Diagnostics completes acquisition of MediSoft

Friday, August 1, 2014 01:43 PM

MGC Diagnostics, a global medical technologies company, has completed its acquisition of MediSoft, a privately held manufacturer of cardiorespiratory diagnostic products based in Belgium.

More... »

U.K. genomics projects granted $505M

Friday, August 1, 2014 01:41 PM

Genomics England’s 100,000 Genomes Project has received a package of investment worth more than $505 million. The four year project focuses on new research to decode 100,000 human genomes—a patient’s personal DNA code.

More... »

FDA approves Jardiance to treat type 2 diabetes

Friday, August 1, 2014 01:33 PM

The FDA has approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes.

More... »

ACRO backs COMPETE Act to expand R&D tax credit

Thursday, July 31, 2014 02:07 PM

On the eve of Congress’ summer departure, an R&D tax credit bill called the COMPETE Act was introduced this morning that would make the R&D tax credit permanent, increase the credit rate to 25% of qualifying research investments and enable investors in small research companies to claim the credit.

More... »

FDA expands approved use of Imbruvica for CLL

Thursday, July 31, 2014 01:55 PM

The FDA has expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a Breakthrough Therapy Designation for this use.

More... »

Noxxon initiates study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol

Thursday, July 31, 2014 01:52 PM

Noxxon Pharma, a biopharmaceutical company developing proprietary therapeutics called Spiegelmers, has treated the first patient with its anti-hepcidin Spiegelmer lexaptepid pegol (NOX-H94) in a phase IIa proof-of-concept clinical trial to treat erythropoietin (EPO) hyporesponsive anemia in dialysis patients.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs